Role of farnesoid X receptor and bile acids in alcoholic liver disease

被引:1
|
作者
Sharon Manley [1 ]
Wenxing Ding [1 ]
机构
[1] Department of Pharmacology, Toxicology and Therapeutics, the University of Kansas Medical Center
基金
美国国家卫生研究院;
关键词
Farnesoid X receptor; Bile acids; Autophagy; Alcoholic liver disease; FoxO3;
D O I
暂无
中图分类号
R96 [药理学];
学科分类号
100602 ; 100706 ;
摘要
Alcoholic liver disease(ALD) is one of the major causes of liver morbidity and mortality worldwide. Chronic alcohol consumption leads to development of liver pathogenesis encompassing steatosis, inflammation, fibrosis, cirrhosis, and in extreme cases, hepatocellular carcinoma. Moreover,ALD may also associate with cholestasis. Emerging evidence now suggests that farnesoid X receptor(FXR) and bile acids also play important roles in ALD. In this review, we discuss the effects of alcohol consumption on FXR, bile acids and gut microbiome as well as their impacts on ALD. Moreover, we summarize the findings on FXR, Fox O3a(forkhead box-containing protein class O3a) and PPARα(peroxisome proliferator-activated receptor alpha) in regulation of autophagy-related gene transcription program and liver injury in response to alcohol exposure.
引用
收藏
页码:158 / 167
页数:10
相关论文
共 50 条
  • [31] Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor
    Dong Renchan
    Yang, Xiaobo
    Wang, Changyuan
    Liu, Kexin
    Liu, Zhihao
    Ma, Xiaodong
    Sun, Huijun
    Huo, Xiaokui
    Fu, Ting
    Meng, Qiang
    PHYTOMEDICINE, 2019, 53 : 134 - 142
  • [32] The role of liver x receptor alpha in non alcoholic fatty liver disease
    Orellana-Gavalda, J. M.
    Terra, X.
    Auguet, T.
    Berlanga, A.
    Guiu, E.
    Sabench, F.
    Aguilar, C.
    Martinez, S.
    Hernandez, M.
    del Castillo, D.
    Richart, C.
    FEBS JOURNAL, 2012, 279 : 275 - 275
  • [33] Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine
    Kim, Insook
    Ahn, Sung-Hoon
    Inagaki, Takeshi
    Choi, Mihwa
    Ito, Shinji
    Guo, Grace L.
    Kliewer, Steven A.
    Gonzalez, Frank J.
    JOURNAL OF LIPID RESEARCH, 2007, 48 (12) : 2664 - 2672
  • [34] Beyond Bile Acids: Targeting Farnesoid X Receptor (FXR) with Natural and Synthetic Ligands
    Carotti, Andrea
    Marinozzi, Maura
    Custodi, Chiara
    Cerra, Bruno
    Pellicciari, Roberto
    Gioiello, Antimo
    Macchiarulo, Antonio
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2014, 14 (19) : 2129 - 2142
  • [35] Yin Yang 1 and farnesoid X receptor: a balancing act in non-alcoholic fatty liver disease?
    Legry, Vanessa
    Schaap, Frank G.
    Delire, Benedicte
    Horsmans, Yves
    Leclercq, Isabelle A.
    GUT, 2014, 63 (01) : 1 - 2
  • [36] Inhibitory Effects of Bile Acids and Synthetic Farnesoid X Receptor Agonists on Rotavirus Replication
    Kim, Yunjeong
    Chang, Kyeong-Ok
    JOURNAL OF VIROLOGY, 2011, 85 (23) : 12570 - 12577
  • [37] Regulation of taurine conjugation and biosynthesis by bile acids through farnesoid X receptor activation
    Miyazaki, Teruo
    Honda, Akira
    Matsuzaki, Yasushi
    HEPATOLOGY RESEARCH, 2014, 44 (10) : E1 - E2
  • [38] Farnesoid X receptor alpha: a molecular link between bile acids and steroid signaling?
    Marine Baptissart
    Aurelie Vega
    Emmanuelle Martinot
    Silvère Baron
    Jean-Marc A. Lobaccaro
    David H. Volle
    Cellular and Molecular Life Sciences, 2013, 70 : 4511 - 4526
  • [39] Farnesoid X receptor alpha: a molecular link between bile acids and steroid signaling?
    Baptissart, Marine
    Vega, Aurelie
    Martinot, Emmanuelle
    Baron, Silvere
    Lobaccaro, Jean-Marc A.
    Volle, David H.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2013, 70 (23) : 4511 - 4526
  • [40] Role of farnesoid X receptor in the enhancement of canalicular bile acid output and excretion of unconjugated bile acids: A mechanism for protection against cholic acid-induced liver toxicity
    Miyata, M
    Tozawa, A
    Otsuka, H
    Nakamura, T
    Nagata, K
    Gonzalez, FJ
    Yamazoe, Y
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (02): : 759 - 766